Guyana vs Malaysia: Statin use vs. average non-HDL cholesterol levels
Guyana
3.9
in 2018
Malaysia
4.2
in 2018
Guyana rank
4th
Malaysia rank
1st
Statin use vs. average non-HDL cholesterol levels over time
- Guyana
- Malaysia
How they compare
Malaysia currently reports 4.2 against 3.9 in Guyana, a difference of 0.3.
That makes Malaysia's figure about 1.1 times Guyana's.
Across all 39 years both countries report, Malaysia has been ahead every year.
Guyana ranks 4th and Malaysia ranks 1st of 191 countries.
Malaysia has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Guyana | Malaysia | Difference | Ahead |
|---|---|---|---|---|
| 1980s | 3.36 | 3.67 | 0.31 | Malaysia |
| 1990s | 3.3 | 3.84 | 0.54 | Malaysia |
| 2000s | 3.46 | 4.09 | 0.63 | Malaysia |
| 2010s | 3.74 | 4.2 | 0.4556 | Malaysia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher statin use vs. average non-hdl cholesterol levels, Guyana or Malaysia?
- Malaysia, at 4.2 against 3.9 in Guyana as of 2018.
- What is the difference in statin use vs. average non-hdl cholesterol levels between Guyana and Malaysia?
- 0.3, with Malaysia ahead.
- How many years of comparable data are there for Guyana and Malaysia?
- 39 years are reported by both, from 1980 to 2018.
- How do Guyana and Malaysia rank globally for statin use vs. average non-hdl cholesterol levels?
- Guyana ranks 4th and Malaysia ranks 1st of 191 countries.
- Where does this data come from?
- World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as Statin use vs. average non-HDL cholesterol levels. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The use of statins in the population. This is compared to average non-HDL cholesterol levels, in mmol/L. Statins are a type of drug that reduce non-HDL cholesterol levels, and are used to treat and prevent cardiovascular diseases in people at heightened risk. Their usage is measured in Defined Daily Doses, per 1,000 people.